verified SJR 0,424 · Q3 • database Scopus / SJR & Web of Science indexed

United Kingdom · SAGE Publications Ltd

workspace_premium Q3 — Medicine (miscellaneous) lock_open Open Access

Journal of Oncology Pharmacy Practice

Journal of Oncology Pharmacy Practice is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 47. It has an SJR impact factor of 0,424 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,424.

Journal of Oncology Pharmacy Practice focuses its scope in these topics and keywords: patients, cell, officebased, carboplatin, transplantation, fluoroquinolone, hematopoietic, dexamethasone, canceradverse, voriconazole, ...

ISSN: 1078-1552

Publisher: SAGE Publications Ltd

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,424 Q3

H-index 47

Acceptance rate pie_chart

33%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,424

H-index

Docs (year)

323

Docs 3y

910

Total refs

8532

Cites 3y

1121

Citable 3y

853

Cites/Doc 2y

1.17

Ref/Doc

26.41

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review

Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience

Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility

Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy

Comparative contamination study with cyclophosphamide, fluorouracil and ifosfamide: standard technique versus a proprietary closed-handling system

Clinical pharmacokinetics and metabolism of paclitaxel after a three-hour infusion: comparison of two preparations

Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature

Chemotherapy-induced moderate tolife-threatening anemia in early-stage breast cancer

Case report on hypersensitivity to methotrexate infusion in a pediatric acute lymphoblastic leukaemia patient

Capecitabine: a novel, orally administered, tumour-activated treatment for breast cancer

Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

SHOW MORE ARTICLES

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin

A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation-review of literature

Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients' online forums

A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel

A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis

A review of imatinib mesilate in the treatment of patients with gastrointestinal stromal tumours and chronic myeloid leukaemia

A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

A Medication Error Prevention Survey: five years of results

A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma

A feasibility study to assess the integration of a pharmacist into neurooncology clinic

A controlled before and after study to evaluate a patient and health professional partnership model towards effective medication reconciliation

FAQs

Journal of Oncology Pharmacy Practice has an SJR of 0,424 (best quartile Q3) in the CountryOfPapers database.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Journal of Oncology Pharmacy Practice is 33%.

Journal of Oncology Pharmacy Practice

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Journal of Oncology Pharmacy Practice?

What is the APC / publication cost?

What is the acceptance rate?